A WHO Ebola vaccine funding review has sparked debate over $60 million in expanded vaccine development using COVID-era platforms. Critics question transparency, while officials emphasize rapid outbreak readiness.
As the WHO and collaborating international institutions spearhead negotiations on monumental regulatory instruments, the stage is set for a seismic shift in the world of global health governance. This isn’t just a tweak in the rulebook; it’s a redefinition of the game itself. The proposed changes, lurking in the undercurrents of diplomatic discussions, threaten to thrust the international administrative landscape into uncharted waters. At the heart of this metamorphosis lies the WHO, wielding growing influence from an array of stakeholders, ranging from corporate giants to authoritarian regimes.